Coherus Biosciences (NASDAQ:CHRS) Rating Increased to C- at TheStreet

Share on StockTwits

Coherus Biosciences (NASDAQ:CHRS) was upgraded by research analysts at TheStreet from a “d-” rating to a “c-” rating in a research note issued on Thursday, TheStreetRatingsTable reports.

Several other equities analysts have also weighed in on the stock. Maxim Group reissued a “buy” rating and issued a $27.00 price objective (up from $25.00) on shares of Coherus Biosciences in a research report on Friday, August 2nd. Credit Suisse Group reissued a “buy” rating and issued a $36.00 price objective on shares of Coherus Biosciences in a research report on Friday. HC Wainwright reissued a “buy” rating and issued a $29.00 price objective (up from $28.00) on shares of Coherus Biosciences in a research report on Friday, August 2nd. Zacks Investment Research raised shares of Coherus Biosciences from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research report on Thursday. Finally, Mizuho set a $43.00 price objective on shares of Coherus Biosciences and gave the company a “buy” rating in a research report on Sunday, September 29th. Two analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Coherus Biosciences presently has an average rating of “Buy” and an average price target of $30.38.

NASDAQ CHRS traded up $0.06 during trading on Thursday, reaching $19.06. 1,353,200 shares of the stock traded hands, compared to its average volume of 992,812. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -5.92 and a beta of 2.90. The stock’s 50-day moving average price is $19.20 and its 200 day moving average price is $19.18. Coherus Biosciences has a fifty-two week low of $8.32 and a fifty-two week high of $23.91.

Coherus Biosciences (NASDAQ:CHRS) last issued its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.63 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.27. The company had revenue of $111.68 million during the quarter, compared to the consensus estimate of $93.58 million. As a group, equities analysts anticipate that Coherus Biosciences will post 0.89 EPS for the current fiscal year.

In related news, COO Vincent R. Anicetti sold 2,500 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $20.03, for a total transaction of $50,075.00. Following the transaction, the chief operating officer now directly owns 21,810 shares of the company’s stock, valued at $436,854.30. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Jean-Frederic Viret sold 1,388 shares of the firm’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $19.02, for a total transaction of $26,399.76. Following the transaction, the chief financial officer now directly owns 6,385 shares in the company, valued at $121,442.70. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,264 shares of company stock worth $504,967. 18.20% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the business. Cutler Group LP acquired a new stake in Coherus Biosciences during the third quarter worth about $32,000. Tower Research Capital LLC TRC acquired a new stake in Coherus Biosciences during the third quarter worth about $52,000. Public Employees Retirement System of Ohio acquired a new stake in Coherus Biosciences during the second quarter worth about $75,000. Aperio Group LLC acquired a new stake in Coherus Biosciences during the second quarter worth about $80,000. Finally, Bank of Montreal Can acquired a new stake in Coherus Biosciences during the second quarter worth about $114,000. Hedge funds and other institutional investors own 96.37% of the company’s stock.

About Coherus Biosciences

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Read More: What is Put Option Volume?

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.